Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Effect of Ensifentrine on Sputum Markers of Inflammation in COPD	Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder	Active, not recruiting	Phase 2	2026-09-30		NCT05270525
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis	Non-cystic Fibrosis Bronchiectasis	Recruiting	Phase 2	2026-08-06		NCT06559150

Clinical trials